
Nutrition and Supplementation in Age-Related Macular Degeneration: Implications for Practice From the AREDS2 10-Year Follow-On Study Update (CE Webcast)
Activity Description and Purpose
This educational activity aims to provide clinicians with advanced knowledge and competence in diagnosing and managing age-related macular degeneration. Presentations will include methods to identify key criteria to diagnose age-related macular degeneration (AMD) in its various stages and emphasizing the role for multimodal imaging. A review of the AREDS2 10-year data on supplementation to prevent AMD progression will be presented, and newer information for potential implications in geographic atrophy will be discussed. Clinicians will learn about the most current evidence to appropriately recommend nutritional supplementation to patients and to counsel them on lifestyle changes that can help prevent progression of AMD. The desired results of this activity are to increase understanding of the most recent data to facilitate appropriate management of AMD and ensure the best possible outcomes for patients.
Target Audience
This educational activity is intended for optometrists.
Learning Objectives
After completing this activity, participants will be better able to:
- Identify diagnostic imaging to correctly diagnose age-related macular degeneration
- Review the AREDS2 10-year data on supplementation to prevent age-related macular degeneration progression
- Apply evidence to appropriately recommend nutritional supplementation to patients with age-related macular degeneration
- Illustrate patient counseling on lifestyle changes according to risk factors for age-related macular degeneration
Faculty
![]() | Jeffry Gerson, OD (Chair) |
![]() | Emily Chew, MD Director, Division of Epidemiology and Clinical Applications Chief, Clinical Trials Branch National Eye Institute National Institutes of Health Bethesda, Maryland |
![]() | Brad M. Sutton, OD Clinical Professor Indiana University School of Optometry Service Chief Indianapolis Eye Care Center Indianapolis, Indiana |
Disclosure Policy
MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any ineligible company. Financial relationship information is collected and resolved prior to the educational activity.
Faculty
Emily Chew, MD, has no relevant relationships with ineligible companies to disclose.
Jeffry Gerson, OD, is a consultant for Bausch & Lomb Incorporated, Essilor of America, Inc, LKC Technologies, Inc, and Macular Degeneration Association, Inc; is an advisory board member of AbbVie Inc, Apellis Pharmaceuticals, AstaReal, Inc, Astellas Pharma Inc, Genentech, Inc, Notal Vision, Optos, Oyster Point Pharma, Inc, Regeneron Pharmaceuticals, Inc, Visionix, Vision Service Plan, and ZeaVision LLC; is on the speakers bureau for Apellis Pharmaceuticals, Astellas Pharma Inc, Bausch & Lomb Incorporated, Genentech, Inc, Oyster Point Pharma, Inc, Regeneron Pharmaceuticals, Inc, Vision Service Plan, and ZeaVision LLC; and is an independent contractor for AbbVie Inc, AstaReal, Inc, Notal Vision, Optos, and Visionix.
Brad M. Sutton, OD, has no relevant relationships with ineligible companies to disclose.
Peer Reviewer
This activity was peer reviewed. The peer reviewer has no relevant relationships with ineligible companies to disclose.
Planners, Managers, and Writers
MedEdicus planners, managers, and writers have no relevant relationships with ineligible companies to disclose.
Accreditation Statement
COPE approved for 1.5 CE credits for optometrists.
COPE Course ID: 96356-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease
Administrator:
This activity, COPE Activity Number 130133, is accredited by COPE for continuing education for optometrists.
Disclosure of Commercial Support
MedEdicus LLC has received commercial support from Bausch & Lomb Incorporated for this activity in the form of an unrestricted educational grant.
The content of this COPE-accredited CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.
Off-Label Discussion
This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.
Sponsored by 
Provider Contact Information
For questions about this educational activity, please contact MedEdicus LLC at [email protected].
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of State University of New York College of Optometry, MedEdicus LLC, or Bausch & Lomb Incorporated.
This CE activity is copyrighted to MedEdicus LLC ©2025. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 326.2
Available Credit
- 1.50 COPE